KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Net Income: 2009-2024

Historic Net Income for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Dec 2024 value amounting to -$278.2 million.

  • Alnylam Pharmaceuticals' Net Income rose 325.05% to $251.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.6 million, marking a year-over-year increase of 113.11%. This contributed to the annual value of -$278.2 million for FY2024, which is 36.82% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Net Income stood at -$278.2 million for FY2024, which was up 36.82% from -$440.2 million recorded in FY2023.
  • Alnylam Pharmaceuticals' 5-year Net Income high stood at -$278.2 million for FY2024, and its period low was -$1.1 billion during FY2022.
  • Moreover, its 3-year median value for Net Income was -$440.2 million (2023), whereas its average is -$616.5 million.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Net Income tumbled by 32.64% in 2022 and then surged by 61.08% in 2023.
  • Over the past 5 years, Alnylam Pharmaceuticals' Net Income (Yearly) stood at -$858.3 million in 2020, then grew by 0.64% to -$852.8 million in 2021, then plummeted by 32.64% to -$1.1 billion in 2022, then soared by 61.08% to -$440.2 million in 2023, then soared by 36.82% to -$278.2 million in 2024.